Elizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be Ignored

By Chadi Nabhan, MD, MBA, FACP - Last Updated: August 1, 2023

In the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology Annual Meeting and Exposition. Dr. Brem discusses which chronic lymphocytic leukemia abstracts from ASH 2022 cannot be ignored, the latest news in Richter’s transformation, and why she is moving away from ibrutinib in her own clinical practice.

HMAs Are ‘Cornerstone’ in High-Risk MDS Treatment, Says Jamile Shammo, MD

Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL

Aaron Goodman, MD, Tells Us the 'Crux' of Castleman Disease

Is MRD Negativity the New Benchmark in ALL Treatment Strategies?

Part Two: Drs. Dahiya, Spiegel Return to Discuss 'Black Box' Warning on CAR-T Therapies

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Elizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be Ignored

Related